Lhermitte sign and urinary retention: atypical presentation of oxaliplatin neurotoxicity in four patients (Q43996948)

28 November 2017

title

Lhermitte sign and urinary retention: atypical presentation of oxaliplatin neurotoxicity in four patients (English)

1 reference

28 November 2017

1 reference

1 reference

1 reference

Sarah Taieb

1 reference

28 November 2017

Véronique Trillet-Lenoir

1 reference

28 November 2017

Loïc Rambaud

1 reference

28 November 2017

Louis Descos

1 reference

28 November 2017

Gilles Freyer

1 reference

28 November 2017

language of work or name

English

0 references

publication date

1 May 2002

1 reference

28 November 2017

1 reference

28 November 2017

1 reference

28 November 2017

1 reference

28 November 2017

page(s)

2434-2440

1 reference

Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer

28 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10500

7 January 2021

Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10500

7 January 2021

Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10500

7 January 2021

Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: A phase II multicentric study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10500

7 January 2021

Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10500

7 January 2021

Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10500

7 January 2021

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10500

7 January 2021

Oxaliplatin: a review of preclinical and clinical studies.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10500

7 January 2021

Oxaliplatin: a review of its use in the management of metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10500

7 January 2021

Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10500

7 January 2021

Neurotoxicity secondary to antineoplastic drugs

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10500

7 January 2021

Comparative adverse effect profiles of platinum drugs.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10500

7 January 2021

Platinum neurotoxicity: clinical profiles, experimental models and neuroprotective approaches

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10500

7 January 2021

Cisplatin neurotoxicity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10500

7 January 2021

Cisplatin-induced peripheral neuropathy. Frequent off-therapy deterioration, demyelinating syndromes, and muscle cramps

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10500

7 January 2021

Ototoxicity of low- and moderate-dose cisplatin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10500

7 January 2021

The development of Lhermitte's sign during cisplatin chemotherapy. Possible drug-induced toxicity causing spinal cord demyelination

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10500

7 January 2021

Spinal cord toxicity complicating treatment with cisplatin and etoposide

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10500

7 January 2021

Cisplatin neuropathy with Lhermitte's sign

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10500

7 January 2021

Cisplatin-induced autonomic neuropathy: does it really exist?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10500

7 January 2021

Seizures and transient cortical blindness associated with cis-platinum (II) diamminedichloride (PDD) therapy in a thirty-year-old man

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10500

7 January 2021

Transient blindness and seizure associated with cisplatin therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10500

7 January 2021

The chemotherapeutic oxaliplatin alters voltage-gated Na(+) channel kinetics on rat sensory neurons

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10500

7 January 2021

Dorsal horn and dorsal column dysfunction in intramedullary cervical cord tumours. A somatosensory evoked potential study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10500

7 January 2021

The contribution of median nerve SEPs in the functional assessment of the cervical spinal cord in syringomyelia. A study of 24 patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10500

7 January 2021

Assessment of Intraspinal and Intracranial Conduction by P30 and P39 Tibial Nerve Somatosensory Evoked Potentials in Cervical Cord, Brainstem, and Hemispheric Lesions

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10500

7 January 2021

Identifiers

DOI

10.1002/CNCR.10500

1 reference

28 November 2017

1 reference